OUR PIPELINE

Aurinia is committed to delivering transformative therapies that address the unmet needs of patients living with autoimmune diseases today – and developing the breakthrough therapies of tomorrow. Our work is rooted in science and at the leading edge of approaches for the treatment of autoimmune and inflammatory diseases. We feel the urgency of finding treatments that enable patients to live their fullest lives and recognize the importance of pursuing research that reflects the diversity of the patients we seek to serve.

Target Discovery & Validation Drug Discovery Lead ID & Optimization IND Enabling Phase 1 Phase 2 Phase 3 U.S. FDA Approval Post-marketing Studies

LUPKYNIS® (voclosporin)

Target Discovery & Validation Phase complete
Drug Discovery Phase complete
Lead ID & Optimization Phase complete
IND Enabling Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
U.S. FDA Approval Phase complete
Post-marketing Studies Phase in progress
Current Phase:
Post-marketing Studies

AUR200

Target Discovery & Validation Phase complete
Drug Discovery Phase complete
Lead ID & Optimization Phase complete
IND Enabling Phase complete
Phase 1 Phase in progress
Current Phase:
Phase 1
Phase 2 Phase not started
Phase 3 Phase not started
U.S. FDA Approval Phase not started
Post-marketing Studies Phase not started
Watch this animation to learn more about how AUR200 works.

AUR200

AUR200 is a highly potent and specific immune modulator of BAFF and APRIL activity. BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) play important roles in regulating B-cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and renal conditions.

AUR200 has a proven mechanism of action.

Aurinia initiated a Phase 1 Single Ascending Dose (SAD) study of AUR200 in the third quarter of 2024. Data from the SAD study, including safety, tolerability, pharmacokinetics, and biomarkers, is anticipated in first half of 2025.

© Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top